Vascular repair utilising immobilised heparin conjugate for protection against early activation of inflammation and coagulation

Summary

Ischaemia-reperfusion injury (IRI) poses a major challenge in many thrombotic conditions and in whole organ transplantation. Activation of the endothelial cells and shedding of the protective vascular glycocalyx during IRI increase the risk of innate immune activation, cell infiltration and severe thrombus formation, promoting damage to the tissue. Here, we present a novel one-step strategy to protect the vasculature by immobilisation of a unique multi-arm heparin conjugate to the endothelium. Applying a new in vitro blood endothelial cell chamber model, the heparin conjugate was found to bind not only to primary human endothelial cells but also directly to the collagen to which the cells adhered. Incubation of hypoxic endothelial cells with freshly drawn human blood in the blood chambers elicited coagulation activation reflected by thrombin anti-thrombin formation and binding of platelets and neutrophils. Immobilisation of the heparin conjugate to the hypoxic endothelial cells created a protective coating, leading to a significant reduction of the recruitment of blood cells and coagulation activation compared to untreated hypoxic endothelial cells. This novel approach of immobilising multi-arm heparin conjugates on the endothelial cells and collagen of the basement membrane ensures to protect the endothelium against IRI in thrombotic disorders and in transplantation.

Keywords

Blood coagulation - endothelial cells - heparin - surface modification - collagen

• References

• 1 Aird WC. Spatial and temporal dynamics of the endothelium. J Thromb Haemost 2005; 03: 1392-1406.
• 2 van Hinsbergh VW. Endothelium--role in regulation of coagulation and inflammation. Semin Immunopathol 2012; 34: 93-106.
• 3 Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nature Rev Immunol 2009; 09: 729-740.
• 4 Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nature Rev Immunol 2013; 13: 34-45.
• 5 Phelan PJ, O’Kelly P, Tarazi M. et al. Renal allograft loss in the first post-operative month: causes and consequences. Clin Transplant 2012; 26: 544-549.
• 6 Singh A, Ramnath RD, Foster RR. et al. Reactive oxygen species modulate the barrier function of the human glomerular endothelial glycocalyx. PloS one 2013; 08: e55852.
• 7 Watts RP, Thom O, Fraser JF. Inflammatory signalling associated with brain dead organ donation: from brain injury to brain stem death and posttransplant ischaemia reperfusion injury. J Transplant 2013; 2013: 521369.
• 8 Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circ Res 2007; 100: 1673-1685.
• 9 Ekdahl KN, Hong J, Hamad OA. et al. Evaluation of the blood compatibility of materials, cells, and tissues: basic concepts, test models, and practical guidelines. Adv Exp Med Biol 2013; 735: 257-270.
• 10 Hong J, Ekdahl KN, Reynolds H. et al. A new in vitro model to study interaction between whole blood and biomaterials. Studies of platelet and coagulation activation acid the effect of aspirin. Biomaterials 1999; 20: 603-611.
• 11 Andersson J, Sanchez J, Ekdahl KN. et al. Optimal heparin surface concentration and antithrombin binding capacity as evaluated with human non-anticoagulated blood in vitro. J Biomed Mater Res A 2003; 67A: 458-466.
• 12 Cabric S, Eich T, Sanchez J. et al. A new method for incorporating functional heparin onto the surface of islets of Langerhans. Tissue Eng Pt C-Meth 2008; 14: 141-147.
• 13 Cabric S, Sanchez J, Johansson U. et al. Anchoring of Vascular Endothelial Growth Factor to Surface-Immobilized Heparin on Pancreatic Islets: Implications for Stimulating Islet Angiogenesis. Tissue Eng Pt A 2010; 16: 961-970.
• 14 Leijon J, Carlsson F, Brannstrom J. et al. Attachment of Flexible Heparin Chains to Gelatin Scaffolds Improves Endothelial Cell Infiltration. Tissue Eng Pt A 2013; 19: 1336-1348.
• 15 Sedigh A, Larsson R, Brannstrom J. et al. Modifying the vessel walls in porcine kidneys during machine perfusion. J Surg Res. 2014. Epub ahead of print
• 16 Kristensen EME, Rensmo H, Larsson R. et al. Characterisation of heparin surfaces using photoelectron spectroscopy and quartz crystal microbalance. Biomaterials 2003; 24: 4153-4159.
• 17 Rodahl M, Kasemo B. A simple setup to simultaneously measure the resonant frequency and the absolute dissipation factor of a quartz crystal microbalance. Rev Sci Instr 1996; 67: 3238-3241.
• 18 Rodahl M, Hook F, Fredriksson C. et al. Simultaneous frequency and dissipation factor QCM measurements of biomolecular adsorption and cell adhesion. Faraday Disc 1997; 107: 229-246.
• 19 Sauerbrey G. Verwendung von Schwingquarzen zur Wägung dünner Schichten und zur Mikrowägung. Z Physik 1959; 155: 206-222.
• 20 Johnell M, Elgue G, Larsson R. et al. Coagulation, fibrinolysis, and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface. J Thorac Cardiovasc Surg 2002; 124: 321-332.
• 21 Nordling S, Nilsson B, Magnusson PU. A novel in vitro model for studying the interactions between human whole blood endothelium. J Vis Exp. 2014. Epub ahead of print
• 22 Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012; 09: 671-675.
• 23 Jones TR, Kang IH, Wheeler DB. et al. CellProfiler Analyst: data exploration and analysis software for complex image-based screens. Bmc Bioinformatics 2008; 09: 482.
• 24 Kett WC, Osmond RIW, Moe L. et al. Avidin is a heparin-binding protein. Affinity, specificity and structural analysis. Bba-Gen Subjects 2003; 1620: 225-234.
• 25 Gong J, Larsson R, Ekdahl KN. et al. Tubing loops as a model for cardiopulmonary bypass circuits: Both the biomaterial and the blood-gas phase interfaces induce complement activation in an in vitro model. J Clin Immunol 1996; 16: 222-229.
• 26 Munoz EM, Linhardt RJ. Heparin-binding domains in vascular biology. Arterioscl Thromb Vasc Biol 2004; 24: 1549-1557.
• 27 Barzu T, Van Rijn JL, Petitou M. et al. Endothelial binding sites for heparin. Specificity and role in heparin neutralisation. Biochem J 1986; 238: 847-854.
• 28 San Antonio JD, Lander AD, Karnovsky MJ. et al. Mapping the heparin-binding sites on type I collagen monomers and fibrils. J Cell Biol 1994; 125: 1179-1188.
• 29 Ogawa S, Gerlach H, Esposito C. et al. Hypoxia Modulates the Barrier and Coagulant Function of Cultured Bovine Endothelium – Increased Monolayer Permeability and Induction of Procoagulant Properties. J Clin Invest 1990; 85: 1090-1098.
• 30 Girn HR, Ahilathirunayagam S, Mavor AI. et al. Reperfusion syndrome: cellular mechanisms of microvascular dysfunction and potential therapeutic strategies. Vasc Endovasc Surg 2007; 41: 277-293.
• 31 Massberg S, Enders G, Matos FCD. et al. Fibrinogen deposition at the postischaemic vessel wall promotes platelet adhesion during ischaemia-reperfusion in vivo. Blood 1999; 94: 3829-3838.
• 32 Heemskerk JWM, Vuist WMJ, Feijge MAH. et al. Collagen but not fibrinogen surfaces induce bleb formation, exposure of phosphatidylserine, and procoagulant activity of adherent platelets: Evidence for regulation by protein tyrosine kinase-dependent Ca2+ responses. Blood 1997; 90: 2615-2625.
• 33 Larsson R, Elgue G, Larsson A. et al. Inhibition of complement activation by soluble recombinant CR1 under conditions resembling those in a cardiopulmonary circuit: reduced up-regulation of CD11b and complete abrogation of binding of PMNs to the biomaterial surface. Immunopharmacology 1997; 38: 119-127.
• 34 Khorana AA, Sahni A, Altland OD. et al. Heparin inhibition of endothelial cell proliferation and organisation is dependent on molecular weight. Arterioscl Throm Vasc Biol 2003; 23: 2110-2115.